Paratek Pharmaceuticals (PRTK) PT Raised to $11 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts PRTK Hot Sheet
Price: $2.23 --0%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Wedbush analyst Robert Driscoll raised the price target on Paratek Pharmaceuticals (NASDAQ: PRTK) to $11.00 (from $9.00) while maintaining a Outperform rating after the company has won a government contract to develop and stockpile Nuzyra (omadacycline) for the treatment of pulmonary anthrax.
- BARDA contract could be worth up to $285M over the next 5 years
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $275 at TD Cowen
- Zimmer Biomet (ZBH) PT Raised to $102 at BMO Capital
- Hut 8 Mining Corp. (HUT) PT Lowered to $127 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
